Navidea Biopharmaceuticals (NAVB)

Navidea (NAVB) Cash flow


Navidea Cash Flow

NAVB's free cash flow for Q3 2023 was $-9.52M. For the 2023 fiscal year, NAVB's free cash flow was decreased by $1.17M and operating cash flow was $-10.25M. See a summary of the company’s cash flow.
Cash Flow
Dec 22Dec 21Dec 20Dec 19Dec 18
Operating Cash Flow
$ -9.71M$ -8.99M$ -10.22M$ -8.17M$ -9.35M$ 4.28M
Investing Cash Flow
$ -701.11K$ -390.35K$ -329.42K$ -412.83K$ 770.42K$ 953.81K
Financing Cash Flow
$ 995.75K$ 7.14M$ 12.18M$ 10.21M$ 6.16M$ -4.55M
Cash Flow From Discontinued Operation
Other Cash Adjustment Inside Changein Cash
End Cash Position
$ 12.04M$ 2.00M$ 4.30M$ 2.67M$ 1.05M$ 3.48M
Income Tax Paid Supplemental Data
Interest Paid Supplemental Data
----$ 8.00K$ 8.00K
Issuance Of Capital Stock
$ 643.79K$ 30.00$ 4.35K$ 10.42M$ 7.09M$ 3.00M
Issuance Of Debt
$ -608.27K$ 1.98M$ -491.77K$ 366.00K$ 0.00-
Repayment Of Debt
$ -908.27K$ -518.09K$ -491.77K$ -368.55K$ -359.06K$ -395.57K
Free Cash Flow
$ -9.16M$ -9.38M$ -10.55M$ -8.59M$ -9.41M$ 4.23M
Domestic Sales
Foreign Sales
Currency in USD

Navidea Cash Flow

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis